Institution
Myriad Genetics
Company•Munich, Germany•
About: Myriad Genetics is a company organization based out in Munich, Germany. It is known for research contribution in the topics: Cancer & Breast cancer. The organization has 562 authors who have published 586 publications receiving 56046 citations. The organization is also known as: Myriad Genetics, Inc..
Topics: Cancer, Breast cancer, Gene, Population, Prostate cancer
Papers published on a yearly basis
Papers
More filters
•
04 Jan 2002TL;DR: In this article, the present invention generally relates to methods for detecting protein-protein interactions, and particularly to two-hybrid for detecting PPI-PPI interactions, which is a two-way hybrid approach.
Abstract: The present invention generally relates to methods for detecting protein-protein interactions, and particularly to two-hybrid for detecting protein-protein interactions.
1 citations
••
TL;DR: A biomarker-based prediction score incorporating a few clinical risk factors appears to have good accuracy to predict CV risk in RA, compared to four simpler CV prediction models.
Abstract: Background: Rheumatoid arthritis (RA) patients are at elevated risk for cardiovascular (CV) events, but risk stratification based on CV prediction models is not part of routine rheumatology practice. Objectives: To develop and validate a biomarker-based CV risk prediction model and compare it to alternative risk prediction models. Methods: We constructed a cohort of RA patients - age ≥40 with ≥1 RA diagnosis from a rheumatologist, excluding patients with malignancy, past myocardial infarction (MI) or stroke - by linking Medicare administrative data from 2006-2016 to multi-biomarker disease activity (MBDA) test results obtained as part of routine care. The cohort was split 2:1 to create training and internal validation datasets. The composite CV outcome was MI, stroke or CV death occurring within 3 years. Clinical predictors examined were: age, sex, race, traditional CV risk factors (e.g. diabetes, hypertension, hyperlipidemia, high-risk CV conditions [e.g. angina]), RA-related factors (e.g. glucocorticoid use, MTX, number of prior biologics), adjusted MBDA score1 and its 12 biomarkers, log-transformed. Backward elimination was used to remove predictors with p ≥0.05. The resulting CV risk score was compared to four prediction models (age+sex; age+sex+CRP; age+sex+diabetes+hypertension+ smoking+high risk CV [±CRP]) in the validation dataset. We evaluated: 1) incremental improvement in the likelihood ratio test (LRT) statistic, 2) discrimination (AUROC), and 3) goodness-of-fit (predicted vs. observed, based on Kaplan-Meier estimates). Validation analyses were prespecified. Results: 30,751 RA patients with 904 CV events were linked to MBDA test results and eligible for analysis. Patient characteristics were mean (SD) age 68.7 (9.5) years; 23.4% age Compared to four simpler CV prediction models, significant improvement in the LRT statistic was observed with the addition of the biomarker-based CV risk score (Figure 1). Model fit was good across deciles (Figure 2). The AUROC was 0.70. The MBDA-based model reclassified 28.5% of patients vs. the model based on age+sex+diabetes+hypertension +smoking+high risk CV+CRP. Conclusion: A biomarker-based prediction score incorporating a few clinical risk factors appears to have good accuracy to predict CV risk in RA. Additional validation in independent cohorts will help verify its performance characteristics. References: [1] Curtis et al., Rheumatology 2018;58:874. Disclosure of Interests: Jeffrey Curtis Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Janssen, Lilly, Myriad, Pfizer, Regeneron, Roche, UCB, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Janssen, Lilly, Myriad, Pfizer, Regeneron, Roche, UCB, Fenglong Xie: None declared, Cynthia S. Crowson Grant/research support from: Pfizer research grant, Brent Mabey Shareholder of: Myriad Genetics, Inc., Employee of: Myriad Genetics, Inc., Darl Flake Shareholder of: Myriad Genetics, Inc., Employee of: Myriad Genetics, Inc., Richard Bamford Shareholder of: Myriad Genetics, Inc., Employee of: Myriad Genetics, Inc., Cheryl Chin Shareholder of: Myriad Genetics, Inc., Employee of: Myriad Genetics, Inc., Eric Sasso Shareholder of: Myriad Genetics, Inc., Employee of: Myriad Genetics, Inc., Elena Hitraya Shareholder of: Myriad Genetics, Inc., Employee of: Myriad Genetics, Inc., Rotem Ben-Shachar Shareholder of: Myriad Genetics, Inc., Employee of: Myriad Genetics, Inc., Alexander Gutin Shareholder of: Myriad Genetics, Inc., Employee of: Myriad Genetics, Inc., Jerry Lanchbury Shareholder of: Myriad Genetics, Inc., Employee of: Myriad Genetics, Inc.
1 citations
••
1 citations
•
20 Aug 2004TL;DR: Methods and pharmaceutical compositions for treating, and delaying the onset of, viral infection, are provided in this article, where the authors also discuss the effects of antiviral drugs on the human body.
Abstract: Methods and pharmaceutical compositions for treating, and delaying the onset of, viral infection, are provided.
1 citations
••
TL;DR: This study evaluated the efficacy and toxicity of neoadjuvant treatment with carboplatin and eribulin in patients with early stage TNBC, and assessed the role of a HRD (homologous recombination deficiency) test to predict response.
Abstract: 1017 Background: Platinum-based chemotherapy has been reported to have efficacy in patients with Triple Negative Breast Cancer (TNBC). Germline BRCA1/2 mutation status has been shown to be predicti...
1 citations
Authors
Showing all 562 results
Name | H-index | Papers | Citations |
---|---|---|---|
Richard D. Smith | 140 | 1180 | 79758 |
Rosalind A. Eeles | 106 | 544 | 45058 |
David E. Goldgar | 103 | 419 | 50450 |
Mark H. Pollack | 89 | 464 | 26511 |
Jacques Simard | 83 | 409 | 28493 |
Julian R. Sampson | 71 | 212 | 22192 |
Johanna M. Rommens | 71 | 202 | 42630 |
David A. Frank | 68 | 201 | 17557 |
Sean V. Tavtigian | 65 | 194 | 35641 |
Mark H. Skolnick | 64 | 211 | 30548 |
Lisa A. Cannon-Albright | 62 | 327 | 28945 |
Alexander Gutin | 54 | 167 | 17705 |
Dominic P. Williams | 49 | 134 | 6665 |
Nelleke A. Gruis | 49 | 159 | 13080 |
Nicola J. Camp | 46 | 213 | 7772 |